Abstract 375P
Background
To determined survival and prognostic factors for non-nasopharyngeal head and neck squamous cell carcinoma (HNSCC) patients treated with surgery followed by concurrent chemoradiotherapy (CCRT) or definitive CCRT (dCCRT), aiming to identify optimal chemotherapy doses.
Methods
This retrospective cohort study reviewed 277 non-NPC HNSCC patients treated with platinum-based CCRT at Rajavithi Hospital between January 1st, 2016 and April 30th, 2021. Clinical features, staging, treatment, and outcomes were collected and analyzed.
Results
Overall, 277 patients were diagnosed as HNSCC; median age: 55.9 years; male: 81.2%; ECOG 0-1: 98.9%. The clinical stage was I-III, IVa, and IVb in 23.8%, 53.4%, and 22.8%, respectively. Cisplatin was used in 39.0%, while carboplatin was used in 61.0%. 53.4% underwent surgery followed by CCRT while 46.6% underwent definitive CCRT. Patients treated with adjuvant CCRT led to significantly longer overall survival (OS) and disease-free survival (DFS) than definitive CCRT (HR: 0.54, p<0.001 for OS; HR: 0.61, p<0.001 for DFS). Higher stage and the presence of pathological risk factors were poor prognostic factors for OS in the adjuvant CCRT group, while higher stage and oral cavity and hypopharynx were associated with poorer OS in the definitive CCRT group. Among the interquartile range of cumulative doses (CDs), the study also found a statistically significant difference in OS and DFS for the dCCRT group with carboplatin at the 2nd Quartile compared to the others (6.75-8.58 AUC) (HR 0.38, 95%CI; 0.17-0.86, p=0.02 and HR 0.41, 95%CI; 0.18-0.91, p=0.03, respectively). There was no significant difference in OS/DFS between patients who received CDs of cisplatin of either less or more than 200 mg/m2 or carboplatin in adjuvant CCRT in all population.
Conclusions
This study showed comparable survival outcomes to historical data. Surgery followed by adjuvant CCRT remains the recommended approach. The CDs of cisplatin or carboplatin did not significantly impact outcomes. A trend towards improved survival with CDs within a specific range requires confirmation in further prospective studies.
Clinical trial identification
6518.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract